PROKIDNEY CORP. (PROK)
PROKIDNEY CORP. (PROK) from its SEC filings: 2025 revenue $893,000 (+1075% vs the year before), net margin -7725%, free cash flow -$135.3 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Revenue (2025) | $893,000 |
| Revenue growth | +1075% |
| Net income | -$69.0 million |
| Net margin | -7725.2% |
| Free cash flow | -$135.3 million |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -32% |
| Cash | $74.9 million |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.